



Privia Medical Group and Javara Selected to Participate in AstraZeneca Phase III Clinical Trial for COVID-19 Vaccine AZD1222

Nov 9, 2020

ARLINGTON, VA – (November 9, 2020) – Privia Medical Group – Gulf Coast (Privia), in partnership with Javara, announced our participation in a Phase 3 clinical trial to test a vaccine against COVID-19. The AZD1222 COVID-19 VACCINE Study, developed by AstraZeneca will research a vaccine candidate intended to protect against the SARS-CoV-2 novel coronavirus.

The U.S. Department of Health and Human Services announced plans to provide up to \$1.2 billion in support for AZD1222 as part of Operation Warp Speed, which aims to have 300 million doses of a safe, effective vaccine for COVID-19 by January 2021.

"We are proud to have been selected alongside such prestigious institutions as Kaiser Permanente – Seattle, NYU Langone Health, and John Hopkins University CRS, to name only a few," said Dr. Keith Fernandez, Chief Clinical Officer at Privia Health. "The need for an effective vaccine in the fight against the COVID-19 pandemic cannot be overstated and we are honored to have the opportunity to participate in a study that is seeking to end this pandemic."

Privia is one of more than 60 national testing locations supporting the AstraZeneca trial, which aims to include 30,000 participants over a period of two years. In partnering with Javara, Privia Health will be able to conduct clinical trials at the point of patient care.

"Javara's research partnership with Privia is a tremendous privilege as we will work alongside the patient volunteers and Privia physician researchers to contribute to this monumental COVID-19 vaccine study. As Houston, Texas is a hub for global medical care and health innovation, it is humbling to be involved and we will work tirelessly to educate, inform, and include a significant number of the total research participants needed," said Jennifer Byrne, Chief Executive Officer at Javara Inc.

Privia will be sourcing patients for its COVID-19 vaccine and treatment trials from within 32 Houston- area practices and will be utilizing an array of recruiting sources with an eye towards ensuring a diverse participant pool.

Those interested in participating in the study should call [346.275.3778](tel:346.275.3778) or visit www.c19vaccinestudy.com to learn more.

About Privia

Privia Health™ is a national physician organization that transforms the healthcare delivery experience for physicians and consumers. Utilizing a platform of talent, tools and highly enabling technology, Privia has a proven track record of developing and elevating physician groups to top tier performance. Their approach of meeting providers where they are on the value continuum and partnering with health plans, health systems, and employers to better align reimbursements to quality, outcomes and performance has proven to be successful and replicable across multiple geographies. This platform of top industry talent, physician leadership development, scalable systems and proprietary technology reduces unnecessary healthcare costs, achieves better outcomes, and improves the health of patients and well being of providers. For more information: www.priviahealth.com. [@PriviaHealth](https://twitter.com/PriviaHealth)

About Javara

Javara is a Winston-Salem, N.C., based Integrated Research Organization (IRO) driven to change the clinical research experience and expand access to clinical trials – for both providers and patients. The Javara team includes experienced clinical research leaders who have collectively led over 10,000 trials and engaged more than 200,000 people in clinical trials. More information about Javara is at Javararesearch.com.